CA Patent

CA3124834A1 — Methods of administration for highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker

Assigned to Milestone Pharmaceuticals Inc · Expires 2023-01-15 · 3y expired

What this patent protects

The present invention is related to use of a therapeutically effective amount of a compound having a structure according to the formula: (see formula I) for treating cardiac arrhythmia, angina, or a migraine in a patient in need thereof, where compound l is formulated for nasal a…

USPTO Abstract

The present invention is related to use of a therapeutically effective amount of a compound having a structure according to the formula: (see formula I) for treating cardiac arrhythmia, angina, or a migraine in a patient in need thereof, where compound l is formulated for nasal administration to the patient in (i) a first dose, and (ii) a second dose of an aqueous composition comprising a pharmaceutically acceptable acetate or methanesulfonate salt of compound l, or a racemate or enantiomer thereof, wherein the acetate or methanesulfonate salt of compound l , or the racemate or enantiomer thereof, is dissolved in the aqueous composition at a concentration of 350 mg/mL~ 50 mg/mL, and wherein the second dose of the compound is to be administered between 5 minutes and 25 minutes after the first dose.

Drugs covered by this patent

Patent Metadata

Patent number
CA3124834A1
Jurisdiction
CA
Classification
Expires
2023-01-15
Drug substance claim
No
Drug product claim
No
Assignee
Milestone Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.